Chronic Heart Failure With Reduced Ejection Fraction Clinical Trial
Official title:
Assessing Vericiguat for the Management of Heart Failure With Reduced Ejection Fraction Using HealthVerity Data
This is an observational study in which the health data of people with chronic heart failure with reduced ejection fraction (HFrEF) are collected using administrative claims data. In observational studies, only observations are made and participants do not receive any advice or changes to healthcare. Chronic HFrEF is a longterm condition that occurs when the heart is weak and cannot pump enough blood to the rest of the body with each heartbeat. This leads to a reduced supply of oxygen which the body requires to function properly. The common symptoms include breathlessness, weakness, fatigue, and swelling in the ankles and legs. If left untreated, heart failure can lead to other serious health problems, including damage to other organs, which may result in hospital stays and even death. Vericiguat works by increasing the activity of an enzyme called soluble guanylate cyclase (sGC), which relaxes the blood vessels and allows more blood to flow through. As a result, the heart is able to pump better. Vericiguat was approved for the treatment of HFrEF based on the results of a study called VICTORIA. The VICTORIA study showed that vericiguat helps in lowering the chances of death or hospitalization due to heart failure. There is limited information available about the use of vericiguat for the treatment of HFrEF under realworld conditions. The main purpose of this study is to collect information about the characteristics of people with HFrEF, who are on vericiguat in addition to at least one standard treatment. Researchers will collect information about participants' basic characteristics, including their age, gender, other health conditions they may have, and the medicines they may be taking. The data will come from administrative claims data for people in the United States of America who were diagnosed with HFrEF between January 2020 and June 2022. In this study, only available data from routine care is collected. No visits or tests are required as part of this study.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02861534 -
A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001)
|
Phase 3 | |
| Completed |
NCT02226120 -
Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction
|
Phase 3 | |
| Recruiting |
NCT06148935 -
An Observational Study to Learn More About the Use of Vericiguat in Korean People With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) in Real-world Setting
|
||
| Active, not recruiting |
NCT05093933 -
A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035)
|
Phase 3 | |
| Not yet recruiting |
NCT06195930 -
A Study to Learn How Safe Starting Vericiguat at a Dose of 5 Milligrams is in Participants With Chronic Heart Failure With Reduced Ejection Fraction
|
Phase 2 | |
| Completed |
NCT04836182 -
A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Participants With Chronic Heart Failure With Reduced Ejection Fraction
|
Phase 2 | |
| Recruiting |
NCT04983043 -
Efficacy and Safety of QiShen YiQi Dripping Pills in Chronic Heart Failure
|
Phase 2 | |
| Active, not recruiting |
NCT04840914 -
A Study of LY3461767 in Participants With Chronic Heart Failure With Reduced Ejection Fraction
|
Phase 1 | |
| Completed |
NCT02768298 -
Exercise Capacity Study of LCZ696 vs. Enalapril in Patients With Chronic Heart Failure and Reduced Ejection Fraction.
|
Phase 4 | |
| Recruiting |
NCT05553886 -
S086 Tablets for Chronic Heart Failure With Reduced Ejection Fraction
|
Phase 3 | |
| Completed |
NCT02900378 -
randOmized stUdy Using acceleromeTry to Compare Sacubitril/valsarTan and Enalapril in Patients With Heart Failure
|
Phase 3 | |
| Withdrawn |
NCT04464525 -
Omecamtiv Mecarbil Post-trial Access Study
|
Phase 3 | |
| Recruiting |
NCT05658458 -
A Study to Learn How Well the Drug Vericiguat Works and How Safe it is Under Real World Conditions in Indian Participants After Worsening of a Long-term Heart Condition in Which the Left Side of the Heart Does Not Pump Blood as Well as it Should (Chronic Heart Failure With Reduced Ejection Fraction)
|
Phase 4 | |
| Recruiting |
NCT05728502 -
An Observational Study, Called VERI-China, to Learn More About How Well Vericiguat Works and How Safe it is in Real-world Setting in People With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) in China
|
||
| Active, not recruiting |
NCT06363110 -
An Observational Study to Learn More About Vericiguat Treatment Patterns and Its Safety in People With Chronic Heart Failure With Reduced Ejection Fraction in Routine Medical Care in the United States
|